Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
The in vitro activity of dirithromycin (LY-237216), a new macrolide erythromycin derivative, was compared to that of four other agents (clarithromycin, erythromycin, roxithromycin, clindamycin) against 334 gram-positive isolates obtained from cancer patients. Dirithromycin was similar in potency and antimicrobial spectrum to the other agents tested. It was very active against beta-haemolytic streptococci and Streptococcus pneumoniae, and moderately active against penicillin and methicillin susceptible Staphylococcus aureus, Bacillus spp., Listeria monocytogenes and Corynebacterium jeikeium. Erythromycin resistant organisms were also resistant to dirithromycin.
Rolston
K V
KV
Department of Medical Specialties, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Ho
D H
DH
LeBlanc
B
B
Bodey
G P
GP
D000900:Anti-Bacterial Agents; D017291:Clarithromycin; D002981:Clindamycin / Q000494:pharmacology; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000150:complications*; D015575:Roxithromycin / Q000494:pharmacology; D018805:Sepsis / Q000150:complications / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D018942:Macrolides; C053853:dirithromycin; D015575:Roxithromycin; D002981:Clindamycin; D004917:Erythromycin; D017291:Clarithromycin